Medication info
Hyundai Valsartan Tablet 80 mg (Valsartan)

Hyundai Valsartan Tablet 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Pale pink, round, biconvex, film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201601688 · Approved 2016.03.30 · Insurance code 642003790

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following several weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1) Children: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Children: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • impaired left ventricular contractile function
View approved original text

This medication is used to effectively control blood pressure in patients with essential hypertension. It is also applicable for heart failure patients who are intolerant to ACE inhibitors belonging to NYHA classification II to IV. After myocardial infarction, it is used to reduce mortality risk in clinically stable patients with left ventricular dysfunction or decreased left ventricular contractile function. Thanks to these efficacies, it helps improve cardiovascular health and reduce the occurrence of related complications. Overall, this medication is used for hypertension, heart failure, and risk reduction post-myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following several weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1) Children: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Children: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Precautions

This medication can cause serious harm to the fetus, especially during pregnancy, and should be discontinued immediately if pregnancy is confirmed. Patients with allergic reactions to this medication or severe liver or kidney impairment should not take it. Individuals with certain conditions, such as the elderly, those with hyperkalemia, or liver impairment, should consult a doctor before use. Blood pressure may drop rapidly upon initial administration, so if dizziness or fainting occurs, medical personnel should be notified immediately. This medication may interact when taken with other antihypertensives, diuretics, or potassium supplements, so patients must inform their medical personnel about any ongoing medications. Particularly, patients with impaired kidney function or diabetes should avoid co-administration with certain drugs and must regularly check kidney function and electrolyte status through blood tests. This medication is not recommended for breastfeeding women. If it must be taken during lactation, breastfeeding should be discontinued. Safety and efficacy have not been established in children or adolescents, so its use is not advisable in this population. Overdosage may result in hypotension and decreased consciousness; seek medical care immediately if this occurs. Dizziness may occur during driving or operating machinery while taking this medicine, so caution is advised. This medication should be kept out of reach of children, and transferring it to another container is not advisable as it may affect the quality of the drug.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture exposure, and it is recommended to maintain a temperature below 30 degrees Celsius. This helps retain the drug's effectiveness over time.

Appearance and packaging

Appearance

Pale pink, round, biconvex, film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.